Inactive Instrument

Spectrum Pharmaceuticals, Inc.

Equities

SPPI

US84763A1088

Biotechnology & Medical Research

Spectrum Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022

March 22, 2023 at 02:45 pm EDT

Spectrum Pharmaceuticals, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was USD 10.11 million. Net loss was USD 75.4 million compared to USD 158.63 million a year ago.

Basic loss per share from continuing operations was USD 0.43 compared to USD 1.02 a year ago. Basic loss per share was USD 0.41 compared to USD 1.02 a year ago.

Latest news about Spectrum Pharmaceuticals, Inc.

Top Midday Decliners	23-08-04	MT
Assertio Therapeutics Completes Acquisition of Spectrum Pharmaceuticals, Reports Lower Q2 Adjusted Earnings	23-08-04	MT
Spectrum Pharmaceuticals, Inc.(NasdaqCM:SPPI) dropped from S&P Global BMI Index	23-08-02	CI
Spectrum Pharmaceuticals, Inc.(NasdaqCM:SPPI) dropped from S&P TMI Index	23-08-02	CI
Assertio Holdings Closes Acquisition of Spectrum Pharmaceuticals	23-08-01	MT
Spectrum Pharmaceuticals, Inc. Announces Cessation of Directors	23-08-01	CI
Spectrum Pharmaceuticals, Inc.(NasdaqCM:SPPI) dropped from NASDAQ Composite Index	23-08-01	CI
Assertio Holdings, Inc. (NasdaqCM : ASRT) completed the acquisition of Spectrum Pharmaceuticals, Inc. (NasdaqGS : SPPI).	23-07-30	CI
Spectrum Pharmaceuticals Regains Nasdaq Compliance	23-05-17	MT
Jefferies Downgrades Spectrum Pharmaceuticals to Hold From Buy, Cuts Price Target to $1.50 From $3.50	23-05-15	MT
Earnings Flash (SPPI) SPECTRUM PHARMACEUTICALS Reports Q1 Revenue $15.6M	23-05-09	MT
Spectrum Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI
B. Riley Lifts Spectrum Pharmaceuticals' Price Target to $1.14 From $1 on Heels of Announced Sale to Assertio Holdings, Keeps Neutral Rating	23-05-08	MT
North American Morning Briefing : Meta Gives Boost -3-	23-04-27	DJ
JMP Securities Downgrades Spectrum Pharmaceuticals to Market Perform From Market Outperform	23-04-26	MT
HC Wainwright Downgrades Spectrum Pharmaceuticals to Neutral From Buy	23-04-26	MT
JMP Securities Downgrades Spectrum Pharmaceuticals to Market Perform From Outperform	23-04-26	MT
Assertio Holdings to Acquire Spectrum Pharmaceuticals	23-04-25	MT
Transcript : Assertio Holdings, Inc., Spectrum Pharmaceuticals, Inc. - M&A Call	23-04-25
Spectrum Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-22	CI
Transcript : Spectrum Pharmaceuticals, Inc., Q4 2022 Earnings Call, Mar 22, 2023	23-03-22
Earnings Flash (SPPI) SPECTRUM PHARMACEUTICALS Posts Q4 Revenue $10.1M	23-03-22	MT
Spectrum Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-22	CI
Alembic Pharmaceuticals Gets Final US FDA for Fluorouracil Injection	23-03-06	MT
Spectrum Pharmaceuticals, Inc. Receives Permanent J-Code for ROLVEDON Injection from U.S. Centers for Medicare & Medicaid Services	23-02-08	CI

Chart Spectrum Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Spectrum Pharmaceuticals, Inc. is a commercial stage biopharmaceutical company. The Company is focused on acquiring, developing, and commercializing targeted oncology therapies. The Company's product portfolio consists of one commercial product and product candidates for the treatment of cancer patients. Its commercial product candidate includes ROLVEDON (eflapegrastim), which is a long-acting granulocyte colony-stimulating factor (G-CSF) that employs a proprietary LAPSCOVERY technology designed to enhance the duration of therapeutic effects and reduce the frequency of administration. ROLVEDON is FDA-approved for the treatment of adult patients with chemotherapy-induced neutropenia. Its development pipeline includes Poziotinib is a novel, pan-HER inhibitor that is designed to irreversibly block signaling through the Epidermal Growth Factor Receptor (EGFR) family of TKIs, including HER1 (erbB1; EGFR), HER2 (erbB2), HER4 (erbB4), and HER receptor mutations.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research